

# MINUTES OF GRIEVANCES MEETING

## MAYO HOSPITAL LAHORE

Venue: Department of Neurology, Mayo Hospital Lahore  
Date & Time: 14-11-2022

### Participants:

- |   |          |
|---|----------|
| 1. Prof. Dr. Ahsan Numan<br>Head of Neurology Department Mayo Hospital Lahore                 | Chairman |
| 2. Prof. Dr. Nasir Chaudhary<br>Head of Ophthalmology Department Unit-II Mayo Hospital Lahore | Member   |
| 3. Mr. Azeem Butt<br>Deputy Drugs Controller Mayo Hospital Lahore                             | Member   |
| 4. Mr. Muhammad Jawad Bhatti<br>Deputy Drugs Controller Mayo Hospital Lahore                  | Member   |

### Proceedings:

Meeting started with the recitation from the Holy Quran. The Chairman, Grievances Committee Mayo Hospital Lahore welcomed all the participants.

**ITEM NO. 01: GRIEVANCE SUBMITTED BY M/S ONCOLINK PHARMA DISTRIBUTORS(TENDER CODE:R01. DRUGS & MEDICINES RETENDER)**

**GRIEVANCE DETAIL:** The firm submitted the grievance under Rule 67(2) of the Punjab Procurement Rules 2014 (PPRA Rules) with reference the Technical Evaluation Report regarding Purchase of Re-Tender Drugs / Medicines (R-01) 2022-23 (Technical Evaluation Report"). The grievance is in response to Less marks in Financial Capacity for tender Items 57 (Zoladex Depot Injection 3.6 mg) & 184 (Dasirox Tablet 400mg). The firm stated that its annual turnover is more than 900 million that could be depicted in attached FBR Tax Return with bid and also attached with the grievance application. The firm argued that according to marking criteria it falls Between 500 million to 1000 million which secures 10 marks but the technical committee granted only 5 marks, so the firm requested to re-evaluate it and grant 10 marks, and consider these products responsive. The firm also raised the grievance in response to Less marks in API Source of Item 57 (Zoladex Depot Injection 3.6 mg). The firm stated that Zoladex Depot Injection 3.6 mg is a research brand and above mentioned product source is FDA approved for which the certificates

*Mr. Ahsan Numan* *ah*

1/2


are attached for reference. The firm requested to consider its item/bid responsive by providing the full marks of the API. The firm also discussed grievance with reference to objection of non-provision of Batch Capacity of the item number 184 (Dasirox Tablet 400mg). In this regard the firm argued that they have attached the Batch Capacity record with grievance application for kind consideration.


**Decision:**


Mr. Zubairi, Sales Manager of M/S Oncolink pleaded the case of firm before the grievances committee. The committee observed that Technical Evaluation Committee (TEC) has disqualified the said items due to failure in Part A & Part B.


The committee observed that Clause 7 of Pat-B Technical Evaluation Parameters required Annual Turnover of last financial year but the firm attached financial statement of Financial Year 2020-21. The committee further observed that the firm failed to provide valid FDA Approval of API as required under clause 4 (i) of Pat-B Technical Evaluation Parameters. The firm provided Batch Capacity Certificate of T.E 184 that has been established after date of tender advertisement. The committee decided to uphold the decision of Technical Evaluation Committee.

*The meeting ended with vote of thanks to and by the Chair.*

  
**Mr. Muhammad Jawad Bhatti**  
Deputy Drugs Controller  
Mayo Hospital Lahore


  
**Prof. Dr. Nasir Chaudhary**  
HoD Ophthalmology Department  
Mayo Hospital Lahore

  
**Mr. Azeem Butt**  
Deputy Drug Controller  
Mayo Hospital Lahore

  
**Prof. Dr. Ahsan Numan**  
HoD Neurology Department  
Mayo Hospital Lahore

AMSP  
under the Rules)

hw  
27/1/22

MSM/HT  
PC-verified  
  
18/1/22

2/2